Successful Financing
Lindis Blood Care Announces Successful Financing for its Tumor-Cell-Removal Medical Device, CATUVAB® Hennigsdorf, Germany: December 12, 2024 Lindis Blood Care, a company aiming to set new standards for blood management during cancer surgeries with its medical device CATUVAB®, today announced the successful first closing of a follow-on financing round. The new investment will be used […]
Positive Top Line Results
Lindis Blood Care Announces Positive Top-Line Results from Clinical Certification Study REMOVE with CATUVAB® to Enable Autologous Blood Transfusion in Cancer Surgeries Hennigsdorf (Berlin), Germany: April 22, 2024 Lindis Blood Care, a company aiming to set a new standard for blood management during cancer surgeries with its medical device CATUVAB®, announced today excellent top-line results from the REMOVE […]
Top Line Results presentation at NATA24
Lindis Blood Care to Present Top Line Results from Clinical Certification Study REMOVE with CATUVAB® at NATA24 Annual Symposium Hennigsdorf (Berlin), Germany: April 11, 2024 Lindis Blood Care, a company aiming to set a new standard for blood Lindis Blood Care, a company aiming to set a new standard for blood management during cancer surgeries with its medical […]
Lindis Blood Care Announces Last Patient Out in Multicenter Clinical Certification Study
Finance News Lindis Blood Care Announces Last Patient Out in Multicenter Clinical Certification Study REMOVE with CATUVAB® to Eliminate Tumor Cells from Surgical Blood Hennigsdorf […]
Lindis’ Catuvab is designed to remove tumor cells from surgical blood
Lindis’ Catuvab is designed to remove tumor cells from surgical blood Hennigsdorf, Berlin, Germany – April 2, 2021. Lindis Blood Care GmbH launched […]